Background Oral zinc has been shown to reduce serum
B
ilirubin enterohepatic circulation is one determinant of neonatal hyperbilirubinemia. 1-3 Studies on animals, adolescents and low birth weight neonates showed that oral zinc salt intake decreased serum bilirubin levels, perhaps through inhibition of the bilirubin enterohepatic circulation. In contrast, a study on at risk healthy term neonates showed that oral zinc did not reduce hyperbilirubinemia in the first week of life. 7 Since these results were inconsistent, we conducted this study to determine the effect of oral zinc on hyperbilirubinemia in full term neonates using time duration measured in hours.
Methods
This randomized, double-blind clinical trial on healthy term neonates who were born spontaneously or through elective caesarean section was conducted at the perinatology ward of Hasan Sadikin Hospital, appropriate for gestational age neonates from singleton School, Hasan Sadikin Hospital, Bandung, Indonesia. Due to the difficulty in determining hyperbilirubinemia mean survival time, we used two proportion formula to determine sample size instead of survival power test. Subjects were collected by consecutive sampling and randomized with block permutation.
Reprint request to
We interviewed mothers to obtain information on maternal age, past illnesses, pregnancy history, drug consumption, history of icterus in previous children, blood type and Rhesus factor. Written informed cord blood total bilirubin levels and determined infant gestational ages by computing from the first day of the last menstrual period and New Ballard score.
Subjects were registered and divided into two groups: the intervention group receiving zinc syrup and the placebo group receiving sucrose syrup, each given twice daily for five days. The syrup supplements 5 mg zinc sulphate and 1.25 mL placebo syrup (coded B) containing sucrose. The placebo was identic in color, appearance and packaging to the zinc sulphate. Syrup supplements were given soon after the first feeding and continued for 5 days by the nurse for subjects in the perinatology ward, or by the mother after discharge from the hospital. Subjects' serum total bilirubin were checked at the time of discharge and day about type of feeding, checked their compliance in giving the supplements by measuring the remaining syrup volumes, and obtained subjects' history of vomitus or diarrhea at home as possible adverse effects of zinc. We also visited subjects at home for those unable to return for the day 5 check. The primary outcome measure was deemed to be the incidence of hyperbilirubinemia, defined as total serum bilirubin Secondary outcome measures were the mean duration of hyperbilirubinemia and the proportion of subjects requiring phototherapy.
Factors related to hyperbilirubinemia (maternal age, gender, umbilical cord bilirubin and type of Hyperbilirubinemia persistence based on time in hours We compared both groups' survival distribution with Results one group receiving zinc and the other receiving sucrose as a placebo. General characteristics of subjects are listed in Table 1. 15 in the zinc group and 11 in the placebo group. Factors related to hyperbilirubinemia were analyzed using chi-square test shown in Table 2 . Figure 1 .
Test of equality of survival distributions by Logrank

Discussion
Bilirubin is produced by the catabolism of heme in the reticuloendothelial system. This bilirubin is in an unconjugated form and is released into the circulation and transported to hepatocytes where it combines enzymatically with glucuronic acid, producing bilirubin mono-and diglucuronides. The conjugation reaction is catalyzed by uridine and the gut. In newborns, much of the conjugated bilirubin in the intestine is hydrolyzed back into unconjugated bilirubin (UCB), a reaction catalyzed by the enzyme beta-glucuronidase present in intestinal mucosa. UCB is reabsorbed into the blood stream by way of the enterohepatic circulation. 1,2 studies have proposed that oral zinc will bind UCB in the intestine to form a structure that cannot be reabsorbed by intestine into the blood stream, such UCB blood levels to decrease. Based on this theory, However, this was not the case, as no significant difference was found in hyperbilirubinemia duration might be caused by several factors affecting neonatal hyperbilirubinemia, e.g. maternal age, subject gender, umbilical cord total bilirubin level, and type of feeding. However, we found no significant difference in the two groups for any of these factors.
may also affect a subject's response to zinc. 8 We assumed there were no pharmacokinetic factors affecting our results, as all subjects had similar physiologic conditions, all parents gave the syrup supplement regularly and in equal dosage, no adverse effects were reported in the zinc group and all subjects were in good health throughout the study. Likewise, no subjects took other medications, thus ruling out drug interactions affecting the results. However, pharmacodynamics may have affected our study. Mendez-Sanchez et al. 5 gave single dose oral zinc adult Gilbert's syndrome patients. They showed a significant decrease in bilirubin serum levels in their subjects. In our study, we gave 5 mg zinc sulphate orally twice daily for five days with no significant decrease in hyperbilirubinemia. It is possible that study results were skewed by low dosage of the zinc
In contrast to previous studies [5] [6] [7] which observed the effect of oral zinc in reducing UCB serum levels based on time measured in days, we measured time in hours. In Rana ' s study 7 in India, oral zinc gluconate was given to subjects starting on the second day of life, whereas, we gave oral zinc soon after the first feeding and observed hyperbilirubinemia based on time in hours and analyzed hyperbilirubinemia duration with zinc and in placebo groups, respectively, that required phototherapy. In agreement with Rana's study, the need for phototherapy not significantly different between the two groups.
There were limitations in our study. For before and after intervention. Nor did we check zinc and bilirubin levels in faeces in our subjects due to limited laboratory facilities. We conclude there was no difference in hyperbilirubinemia duration in full term neonates who received oral zinc versus those who received a placebo.
